Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;166(3):1337-1344.
doi: 10.1002/ijgo.15513. Epub 2024 Apr 8.

Expression of netrin-1 in uterine serous carcinoma and its association with prognosis

Aysegul Ucuncu Kefeli  1 , Busra Yaprak Bayrak  2 , Esra Betul Tunce  2 , Cigdem Vural  2 , Ibrahim Halil Suyusal  1 , Umut Kefeli  3 , Maksut Gorkem Aksu  1
Affiliations

Expression of netrin-1 in uterine serous carcinoma and its association with prognosis

Aysegul Ucuncu Kefeli et al. Int J Gynaecol Obstet. 2024 Sep.

Abstract

Background/objectives: At present, there are few biomarkers used to predict the prognosis of uterine serous carcinoma (USC). Netrin-1 may be a promising biomarker candidate. We investigated netrin-1 expression in USC tissues and healthy endometrial tissues to determine its relevance to disease prognosis.

Materials and methods: Netrin-1 expression was examined in the tissues of 48 patients with USC and 30 patients with healthy benign endometrial tissues via immunohistochemistry.

Results: None of the healthy tissues were stained with netrin-1. In tumor tissues, the overall positivity rate of netrin-1 was 75%, detected as high expression in 17 patients (35%) and low in 19 (40%). Patients who had tumors with no netrin-1 expression (n = 12) had a median overall survival (OS) of 60.0 months (95% confidence interval [CI], 47-98), whereas patients who had tumors with low to strong netrin-1 expression (n = 33) had a lower median OS of 50 months, but the difference was not statistically significant (95% CI, 58-108; P = 0.531). Disease-free survival (DFS) was not statistically significant between the groups (95% CI, 67.7-115.9; P = 0.566). Patients with a tumor diameter ≥2 cm had higher netrin-1 expression than those with a tumor diameter of 2 cm (P = 0.027). We did not find any difference in overall and DFS when age, tumor stage, histology, tumor diameter, p53 status, lymphovascular space invasion, myometrial invasion, and lymph node metastasis were compared according to netrin-1 expression (P > 0.05).

Conclusion: Netrin-1 was expressed in USC but not in healthy tissues. Its expression was not associated with OS or DFS.

Keywords: biomarker; immunohistochemistry; netrin‐1; prognosis; uterine serous carcinoma.

PubMed Disclaimer

References

REFERENCES

    1. Ferlay J, Ervik M, Lam F, et al. Global CancerObservatory: Cancer Today. Lyon, France: International Agency for Research onCancer. 2024. Accessed April 4, 2024. https://gco.iarc.who.int/today/en
    1. Bogani G, Ray‐Coquard I, Concin N, et al. Uterine serous carcinoma. Gynecol Oncol. 2021;162(1):226‐234.
    1. Ferriss JS, Erickson BK, Shih IM, Fader AN. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer. 2021;31(8):1165‐1174.
    1. McGunigal M, Liu J, Kalir T, Chadha M, Gupta V. Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a national cancer database analysis. Int J Gynecol Cancer. 2017;27(1):85‐92.
    1. Fader AN, Boruta DM, Olawaiye AB, Gehrig PA. Uterine papillary serous cancer: epidemiology, pathogenesis, and management. Curr Opin Obstet Gynecol. 2012;22:21‐29.

LinkOut - more resources